Biology and Clinical Evaluation of T/NK Cell Engagers
Cancer Drug Discovery and Development, ISSN: 2196-9914, Page: 329-351
2022
- 2Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Captures2
- Readers2
Book Chapter Description
Bispecific engagers are cancer immunotherapeutics that incorporate at least two antigen recognition domains and engager both a tumor-associated antigen and an immune effector cell surface molecule to facilitate targeted antitumor activity. This strategy is most advanced for CD19+ B cell malignancies, where the CD19xCD3 bispecific T cell engager (BiTE) blinatumomab has achieved FDA approval. However, efforts are underway to expand the application of this technology to other malignancies. This chapter reviews design strategies to decrease immunogenicity, alter kinetics, enhance effector function, optimize antigen recognition, and direct specific assembly. Additionally, we explore alternative immune effector cell platforms and delivery methods. We describe the landscape of ongoing clinical studies of bispecific T cell and natural killer cell engagers for hematologic malignancies and solid tumors. As the clinical translation of bispecific immune cell engagers continues to advance, key additional considerations include the impact of the host immune environment, integration with other immune and conventional therapies, and mitigation of toxicities.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85122474654&origin=inward; http://dx.doi.org/10.1007/978-3-030-87849-8_17; https://link.springer.com/10.1007/978-3-030-87849-8_17; https://dx.doi.org/10.1007/978-3-030-87849-8_17; https://link.springer.com/chapter/10.1007/978-3-030-87849-8_17
Springer Science and Business Media LLC
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know